Investor deploying $1.2M into TNDM, betting on PayGo's 2027 projections and market opportunity as competitors like Insulet and Mint struggle with product execution in the insulin pump space. Key risks include competition from newer tubeless pump alternatives and execution delays on PayGo launch.